Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05174780 · ClinicalTrials.gov registry record · NA
Myopia Control With a Innovative Spectacle Lens
A NA study of Myopia, sponsored by Essilor International.
- Completed
- Registry status
- NA
- Development phase
- 159
- Enrollment target
- 9
- Study locations
NCT05174780: Completed NA study of Myopia, sponsored by Essilor International.
NCT05174780 is a NA study of Myopia that has completed, run by Essilor International. The registered enrollment target is 159 participants, below the 266-participant average among 90 other Myopia trials with a reported enrollment target (40% lower). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05174780, a NA study of Myopia, has completed, sponsored by Essilor International.
- COMPLETED
- Registry status
- NA
- Development phase
- 159 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to demonstrate that the test spectacle lens is safe and effective in slowing myopia progression in children.
Primary Outcome
Change in axial length from baseline
Conditions Studied
Interventions
- DEVICE innovative myopia control spectacle lens
- DEVICE Single vision spectacle lens
Study Locations (9)
New York
- SUNY College of Optometry - New York
- Sacco Eye Group - Vestal
California
- Scripps Poway Optometry - San Diego
Florida
- Sabal Eye Care - Longwood
Illinois
- Illinois College of Optometry - Chicago
Kansas
- Kannarr Eye Care - Pittsburg
Massachusetts
- New England College of Optometry - Boston
Pennsylvania
- UPMC Children's Hospital of Pittsburgh - Pittsburgh
Texas
- Mann Eye Institute - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2021-12-29 |
| Est. Completion | 2025-10-20 |
| Phase | NA |
What the finished NCT05174780 record still lists
NCT05174780 is an interventional study that assigns participants to a tested intervention. The registered 159 participants enrollment target is mid-sized for trials with a published cap, below the 266-participant average among 90 other Myopia trials with a reported enrollment target (40% lower).
The record links to 1 condition, with Myopia appearing as the primary indexed condition, and to 2 interventions - of which innovative myopia control spectacle lens is the first listed.
NCT05174780 lists 9 locations in 8 states (New York, California, Florida).
Frequently Asked Questions
What is clinical trial NCT05174780 about?
NCT05174780 is a clinical study titled "Myopia Control With a Innovative Spectacle Lens". The purpose of this study is to demonstrate that the test spectacle lens is safe and effective in slowing myopia progression in children.
What is the current status of trial NCT05174780?
This trial is currently completed. It is a NA study. The enrollment target is 159 participants. The study started on 2021-12-29. Estimated completion is 2025-10-20.
What conditions does trial NCT05174780 study?
This clinical trial studies the following conditions: Myopia.
What interventions are being tested in trial NCT05174780?
The interventions under investigation include: innovative myopia control spectacle lens (DEVICE), Single vision spectacle lens (DEVICE).
Who is sponsoring clinical trial NCT05174780?
This trial is sponsored by Essilor International, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05174780 being conducted?
This trial has 9 study locations across California, Florida, Illinois, Kansas, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05174780's enrollment target sits among peer trials
159 29th of 90 higher than 62 of 90 other Myopia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy of Repeated Low-level Red-light Therapy in Myopia Control
RECRUITING · NA
-
Comprehensive Assessment of Multiple Products (CAMP)
RECRUITING · NA
-
Children's Viewing Behavior
RECRUITING · NA
-
Violet Light for the Suppression of Myopia
RECRUITING · NA
-
Measuring Outcomes of LASIK and EVO-ICL in Matched Populations
RECRUITING · NA
-
Wavelength Intervention for Nearsighted Kids
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05267626 · 159 participants · Phase 1
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- NCT06321575 · 159 participants · NA
The Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial)
- NCT06729151 · 159 participants
Effect of Intradetrusor onabotulinumtoxinA Injection Versus Conservative Management on Female Sexual Function in Patients With Bladder Pain Syndrome
- NCT07023731 · 159 participants · Phase 1
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI